Ertugliflozin is a potent and selective inhibitor of the sodium-dependent glucose cotransporter 2(SGLT2); increases the excretion of glucose with a 2,000-fold selectivity over SGLT1 (IC50 = 0.877 and 1,960 nM, respectively, for human isoforms in vitro. MW: 436.89. Purity ≥98% by HPLC